
R-Biopharm AG





Therapeutic drug monitoring (TDM) with RIDASCREEN[®] & RIDA[®]QUICK

Therapeutic drug monitoring of TNFalpha blockers such as infliximab or adalimumab and of the $\alpha 4\beta 7$ integrin-antagonist vedolizumab helps to optimize the treatment of patients and to improve therapy outcomes.

Key features of R-Biopharm's TDM portfolio:

- All TDM assays of R-Biopharm AG are validated by KU Leuven, Belgium
- ELISAs and rapid assays correspond due to identical monoclonal antibodies
- The assays have ready to use reagents
- RIDASCREEN[®] ELISAs are validated on automated ELISA readers such as DSX[®] and have breakable microwell plates
- The rapid point of care assays RIDA®QUICK IFX Monitoring and RIDA®QUICK ADM Monitoring allow the determination of trough level concentration of infliximab and its biosimilars and adalimumab, respectively within 20 minutes





RIDA®QUICK IFX Monitoring, Art. No. GN3041



Products for therapeutic drug monitoring (TDM)

Infliximab lateral flow assay

	Product	Description	Tests	Matrix	Art. No.
		Lateral flow test and device			
	RIDA [®] QUICK IFX Monitoring	Immunochromatographic lateral flow assay for the quantitative determination of infliximab (IFX) and its biosimilars	25	Serum/plasma	GN3041
	RIDA [®] QUICK IFX Monitoring Control Set	Positive controls • accessory for GN3041			GP3041
ew	RIDA [®] QUICK ADM Monitoring	Immunochromatographic lateral flow assay for the quantitative determination of adalimumab (ADM)	25	Serum/plasma	GN3043
ew	RIDA [®] QUICK ADM Monitoring Control Set	Positive controls • accessory for GN3043			GP3043
	RIDA®QUICK SCAN II - IVD SET	Lateral flow reader (CE-IVD) and 2D barcode scanner • for read out of GN3041 and GN3043			ZRQS2-KD SET

ELISAs based on assays of KU Leuven, Belgium

	Enzyme immunoassay			Lune -
RIDASCREEN [®] IFX Monitoring	Enzyme immunoassay for the quantitative determination of infliximab (IFX) and its biosimilars	96	Serum/plasma	G09041
RIDASCREEN®Anti-IFX Antibodies	Enzyme immunoassay for the quantitative determination of antibodies to infliximab (IFX) and its biosimilars	96	Serum/plasma	G09042
RIDASCREEN [®] ADM Monitoring	Enzyme immunoassay for the quantitative determination of adalimumab (ADM)	96	Serum/plasma	G09043
RIDASCREEN® Anti-ADM Antibodies	Enzyme immunoassay for the quantitative determination of antibodies to adalimumab (ADM)	96	Serum/plasma	G09044
RIDASCREEN [®] VDZ Monitoring	Enzyme immunoassay for the quantitative determination of vedolizumab (VDZ)	96	Serum/plasma	G09045

More assays related to IBD and IBS diagnostics

Enzyme immunoassay and lateral flow assay			The second	
RIDASCREEN [®] Calprotectin	Enzyme immunoassay for the quantitative determination of calprotectin	96	Stool	G09036

For further details and information visit our website www.r-biopharm.com, contact your local distributor or Clinical Sales International.

R-Biopharm contacts:

 Clinical Sales International:

 Phone: +49 (0) 61 51 - 81 02-0

 Fax: +49 (0) 61 51 - 81 02-688

 E-mail: clinical.sales@r-biopharm.de

 Order Department:

 Phone: +49 (0) 61 51 - 81 02-0

 Fax: +49 (0) 61 51 - 81 02-20

 E-mail: orders@r-biopharm.de